Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) and Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Volatility & Risk
Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Earnings & Valuation
This table compares Shionogi & Co., Ltd. Unsponsored ADR and Jazz Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shionogi & Co., Ltd. Unsponsored ADR | $3.32 billion | 4.88 | $1.35 billion | $1.00 | 9.52 |
| Jazz Pharmaceuticals | $4.27 billion | 3.29 | -$356.15 million | $14.50 | 14.90 |
Shionogi & Co., Ltd. Unsponsored ADR has higher earnings, but lower revenue than Jazz Pharmaceuticals. Shionogi & Co., Ltd. Unsponsored ADR is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Shionogi & Co., Ltd. Unsponsored ADR and Jazz Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shionogi & Co., Ltd. Unsponsored ADR | 0 | 0 | 0 | 3 | 4.00 |
| Jazz Pharmaceuticals | 0 | 2 | 17 | 1 | 2.95 |
Jazz Pharmaceuticals has a consensus target price of $292.05, suggesting a potential upside of 35.20%. Given Jazz Pharmaceuticals’ higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.
Institutional & Insider Ownership
1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Shionogi & Co., Ltd. Unsponsored ADR and Jazz Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shionogi & Co., Ltd. Unsponsored ADR | 46.67% | 16.13% | 12.09% |
| Jazz Pharmaceuticals | 20.45% | 33.97% | 13.02% |
Summary
Jazz Pharmaceuticals beats Shionogi & Co., Ltd. Unsponsored ADR on 10 of the 15 factors compared between the two stocks.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson’s disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
